NCT06890650 A Study to Evaluate the Effect of Fecal Transplant and Dietary Changes on Disease Activity in Patients With Newly Diagnosed Active Crohn Disease
| NCT ID | NCT06890650 |
| Status | Recruiting |
| Phase | — |
| Sponsor | All India Institute of Medical Sciences |
| Condition | Crohn Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 168 participants |
| Start Date | 2025-03-15 |
| Primary Completion | 2027-03-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 168 participants in total. It began in 2025-03-15 with a primary completion date of 2027-03-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Dysbiosis can be rectified by several methods: antibiotics, prebiotics, probiotics, dietary modulation, and fecal microbiota transplantation. There has been limited success with the isolated use of antibiotics and pre/probiotics in the treatment of IBD. Among the measures of dietary manipulation, the use of exclusive enteral nutrition (EEN) has shown superior, or at least equivalent, efficacy compared with steroids in pediatric CD. Although the results in adults are not as encouraging, recent cohort studies in patients with complicated CD have shown good success rates. Definite exclusion diets that exclude pro-inflammatory dietary constituents have also been tested with good clinical efficacy in patients with CD, who even failed treatment with anti-TNF agents. Various dietary approaches, inclusive of exclusive enteral nutrition, partial enteral nutrition, and Crohn's disease exclusion diet have been reported to be of benefit and are associated with changes in gut microbiome. Fecal microbiota transplantation (FMT) defined as the infusion of fecal suspension from a healthy individual into the gastrointestinal tract of an individual with GI disease carries a diverse population of microbiota and their metabolites and has been tested with varying efficacy in IBD. In general, FMT has shown good success rates in randomized control trials in patients with UC who failed conventional agents. Although limited small RCTs exist in CD, cohort studies have also shown good success rates. Therefore, the use of FMT in addition to standard medical therapy, is a concept that has not been previously explored and forms the basis for the present study. Therefore, a well-powered RCT is required to resolve the role of FMT in CD. In this study, patients will be recruited in four arms. Group A includes FMT+CDED+SMT, in Group B FMT+SMT+SHAM DIET, in Group C Sham FMT+CDED+SMT, in Group D Sham FMT+ Sham Diet+ SMT given. 168 patients will be recruited across 6 centers for around 3 years. Follow-up of the patient will be done at 0,2,6 and 10 weeks and 8 weekly up to 48 weeks.
Eligibility Criteria
Inclusion Criteria: 1. Patients with treatment-naive Crohns disease accessible with ileocolonoscopy 2. Symptom onset of less than 12 months 3. Mild to moderate disease activity with endoscopically active disease 1. CDAI of greater than 150 and less than 450 2. SES-CD of or equal to or greater than 6 (or equal to or greater than 4 if isolated ileal disease) 4. Aged between 18-75 years Exclusion Criteria: 1. Patients with severe disease (CDAI greater than 450, SES-CD greater than 16) or requiring hospitalization 2. Patients who have been received on corticosteroids, immunosuppressants (azathioprine/ 6- mercaptoprine/methotrexate) for greater than 2 weeks 3. Biologicals or small molecule exposure 4. Stricturing (non-passable stricture), fistulising phenotype or perianal fistula/abscess 5. L4 disease 6. Pregnant or lactating women 7. Previous surgery for CD 8. Declining consent 9. Not willing for FMT/Dietary advise 10. Patients with current or recent history of clinically severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, metabolic, endocrine, pulmonary, cardiac, or neurological disease. 11. Positive assay or stool culture for pathogens (ova and parasite examination, bacteria) or positive test for Clostridioides difficile toxin at screening# 12. Patients infected with human immunodeficiency virus (HIV) # The patients with positive assay will be treated appropriately and tests will be repeated. Those with negative assay and persistent activity will be included in the study.
Contact & Investigator
Prof Vineet Ahuja, DM Gastroenterology
PRINCIPAL INVESTIGATOR
Department of Gastroenterology, AIIMS, New Delhi
Frequently Asked Questions
Who can join the NCT06890650 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Crohn Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06890650 currently recruiting?
Yes, NCT06890650 is actively recruiting participants. Contact the research team at vineet.aiims@gmail.com for enrollment information.
Where is the NCT06890650 trial being conducted?
This trial is being conducted at Kochi, India, Mumbai, India, New Delhi, India, Ludhiana, India and 2 additional locations.
Who is sponsoring the NCT06890650 clinical trial?
NCT06890650 is sponsored by All India Institute of Medical Sciences. The principal investigator is Prof Vineet Ahuja, DM Gastroenterology at Department of Gastroenterology, AIIMS, New Delhi. The trial plans to enroll 168 participants.